ESMO and WCLC: Latest developments in EGFR mutated NSCLC
18 Oct 2024
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Assessment of suicide risk in cancer patients
Cancer journeys: Research from India
Depression in cancer